Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
Federal funding opportunity FOR-FD-24-008 from Food and Drug Administration.
View forecast on Grants.gov →Forecasted — not yet open
- Posted
- November 24, 2023
- Closes
- See announcement
- Award ceiling
- $350,000
- Award floor
- $350,000
- Expected awards
- 1
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.103
- Category
- Agriculture, Consumer Protection, Food and Nutrition
Program funding history
Awards made under Assistance Listing 93.103 across FY2024–FY2026, from public federal spending records.
- FY2024 obligated
- $250.8M
- FY2025 obligated
- $213M
- FY2026 (to date) obligated
- $15M
- Awards in window
- 911
Top recipients: The Critical Path Institute, National Environmental Health Association, Association of Food & Drug Officials, The Medical Device Innovation Consortium, Duke University
Source: USAspending.gov · refreshed July 2026
Synopsis
The Food and Drug Administration's (FDA), Center for Drug Evaluation and Research (CDER), Office of New Drugs (OND), is announcing this Funding Opportunity Announcement (FOA) for a Cooperative Agreement.
The proposed work directly supports the U.S. FDA’s stated goal of protecting public health from unacceptable risks from nitrosamine impurities in human drugs. Although significant experimental and policy/regulatory initiatives have been undertaken in this area, there remains a need for further research into and development and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The aim is to improve the safety of human drugs with potential nitrosamine impurity liabilities.
In addition to the work outlined above, the award recipient will assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends.
Who can apply
- Public housing authorities/Indian housing authorities
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Public and State controlled institutions of higher education
- Small businesses
- Native American tribal organizations (other than Federally recognized tribal governments)
- State governments
- Special district governments
- County governments
- City or township governments
- Native American tribal governments (Federally recognized)
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Independent school districts
- For profit organizations other than small businesses
- Private institutions of higher education
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.The FDA will not accept duplicate or highly overlapping applications under review at the same time. This means that the FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statementfrom the review of the previous new (A0) application.
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.
Similar grants
- Renewable Energy Systems and Energy Efficiency Improvements Program
- Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not Allowed
- NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens
- Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
- Vet-LIRN Capacity-Building Project and Equipment Grants (U18)
- Laboratory Flexible Funding Model (LFFM)
Never miss a funding deadline again
Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.
Get funding alerts